Cell Biotech Co., Ltd.

A049960

KR7049960008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 04/07/2024 BST			5-day change	1st Jan Change
13,500 ^KRW	+1.89%		+3.37%	+20.32%

2023	Cell Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2022	Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.	CI

Cell Biotech Co., Ltd. authorizes a Buyback Plan.

July 30, 2019

The Board of Directors of Cell Biotech Co., Ltd. has authorized a buyback plan on July 31 2019.

Latest news about Cell Biotech Co., Ltd.

Cell Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.	18/08/22	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.	18/08/22	CI
Cell Biotech Co., Ltd.'s Equity Buyback announced on February 18, 2022, has expired with 227,719 shares, representing 3.24% for KRW 3,718.70 million.	17/08/22	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.	19/05/22	CI
Cell Biotech Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	18/02/22	CI
Cell Biotech Co., Ltd. authorizes a Buyback Plan.	17/02/22	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/07/21	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/07/21	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/07/21	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/07/21	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/07/21	CI
Cell Biotech Co., Ltd.'s Equity Buyback announced on July 31, 2019, has expired with 432,381 shares, representing 5.8% for KRW 7,328 million.	28/07/21	CI
Cell Biotech Acquire a European Patent for Anticancer Protein P8 Originated from Lactobacillus rhamnosus	06/04/21	CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till July 29, 2021.	28/01/21	CI
Cell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI Index	21/09/20	CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till January 29, 2021.	28/07/20	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	29/06/20	CI
Psomagen and Cell Biotech to Enter into Agreement	21/06/20	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/03/20	CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till July 29, 2020.	29/01/20	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	30/12/19	CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.	29/09/19	CI
Cell Biotech Co., Ltd. announces an Equity Buyback for KRW 10,000 million worth of its shares.	31/07/19	CI
Cell Biotech Co., Ltd. authorizes a Buyback Plan.	30/07/19	CI

CELLBIOTECH Co., Ltd is a Korea-based company engaged in the manufacturing of bio products. The Company's products include lactic acid bacteria (LAB) powders and finished products containing LABs. Its LAB powders are used as raw materials in foods and medicines for the functions of immunization enhancement and digestion improvement. Its finished products containing LABs are used for intestinal health improvement, carcinogen inhibition, calcium supplement and others. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CELL BIOTECH CO., LTD.	+20.32%	66.97M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B